Standout Papers
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study (2008)
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007)
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017)
Immediate Impact
2 by Nobel laureates 27 from Science/Nature 118 standout
Citing Papers
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
2020 Standout
A view on drug resistance in cancer
2019 StandoutNature
Works of Stephen G. O’Brien being referenced
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
2010
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
2007 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Stephen G. O’Brien | 3709 | 3058 | 2017 | 43 | 4.4k | |
| Neil J. Gallagher | 3099 | 2640 | 1793 | 68 | 4.2k | |
| Gabriel Étienne | 5151 | 4198 | 2425 | 108 | 6.0k | |
| Zbigniew Rudzki | 2650 | 2185 | 1523 | 101 | 3.7k | |
| Eric Bleickardt | 3254 | 2368 | 1609 | 39 | 3.9k | |
| Laurence Legros | 3531 | 2662 | 1492 | 126 | 4.0k | |
| Susan O’Brien | 4258 | 3395 | 1909 | 73 | 5.7k | |
| Thomas O’Hare | 3698 | 2879 | 1673 | 116 | 5.5k | |
| Mary Beth Rios | 6162 | 4913 | 3413 | 129 | 7.3k | |
| Shu Tamura | 2508 | 1591 | 1120 | 12 | 3.7k | |
| Jaspal Kaeda | 3509 | 2747 | 1844 | 68 | 4.2k |
All Works
Loading papers...